Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride

Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.

[1]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[2]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[3]  C D Marsden,et al.  The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.

[4]  A. Antonini,et al.  [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.

[5]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.

[6]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  K. L. Leenders,et al.  Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.

[8]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[9]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[10]  K. Jellinger,et al.  The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.

[11]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[12]  G. Antoni,et al.  Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography , 1990, Acta neurologica Scandinavica.

[13]  P. Hartvig,et al.  Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone , 1987, Acta neurologica Scandinavica.

[14]  J. Rinne,et al.  Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.

[15]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[16]  S. Snyder,et al.  Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.

[17]  U Ruotsalainen,et al.  PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[18]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[19]  C. Halldin,et al.  A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[20]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[21]  C. Nahmias,et al.  Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[22]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[23]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[24]  H. Kimura,et al.  Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.

[25]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[26]  H Lundqvist,et al.  Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease , 1988, Acta neurologica Scandinavica.

[27]  M. Raichle,et al.  MPTP‐induced up‐regulation of in vivo dopaminergic radioligand‐receptor binding in humans , 1987, Neurology.

[28]  U Ruotsalainen,et al.  Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  J. Rinne,et al.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[30]  C. Patlak,et al.  Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.

[31]  D B Calne,et al.  Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.

[32]  P. Spano,et al.  Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. , 1978, Advances in biochemical psychopharmacology.